NewzNovartis has reported positive results from the Phase 2 TRANQUILITY study, in which its newly acquired drug, pacibekitug, demonstrated a sustained reduction in biomarkers of inflammation. The midstage trial focused on the drug's ability to lower inflammatory signs, marking a preliminary step in evaluating its potential utility.
Following these findings, industry experts are awaiting further details regarding Novartis's strategic plans for the drug's development. The company is currently assessing whether pacibekitug can be effectively advanced as a therapeutic option for improving cardiovascular outcomes.
In-depth summary · AI, neutral